JP2006511473A - 蛍光染料及びmri造影剤を含む二元機能造影剤 - Google Patents
蛍光染料及びmri造影剤を含む二元機能造影剤 Download PDFInfo
- Publication number
- JP2006511473A JP2006511473A JP2004537651A JP2004537651A JP2006511473A JP 2006511473 A JP2006511473 A JP 2006511473A JP 2004537651 A JP2004537651 A JP 2004537651A JP 2004537651 A JP2004537651 A JP 2004537651A JP 2006511473 A JP2006511473 A JP 2006511473A
- Authority
- JP
- Japan
- Prior art keywords
- dual function
- detection reagent
- function detection
- component
- optical imaging
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000009977 dual effect Effects 0.000 title claims abstract description 99
- 239000002872 contrast media Substances 0.000 title abstract description 63
- 239000002616 MRI contrast agent Substances 0.000 title description 14
- 239000007850 fluorescent dye Substances 0.000 title 1
- 238000001514 detection method Methods 0.000 claims abstract description 98
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 97
- 238000012634 optical imaging Methods 0.000 claims abstract description 76
- 238000000034 method Methods 0.000 claims abstract description 29
- 238000001727 in vivo Methods 0.000 claims abstract description 12
- 230000002503 metabolic effect Effects 0.000 claims abstract description 12
- 230000000694 effects Effects 0.000 claims abstract description 10
- 238000003776 cleavage reaction Methods 0.000 claims abstract description 8
- 230000007017 scission Effects 0.000 claims abstract description 8
- 238000011503 in vivo imaging Methods 0.000 claims abstract description 5
- 238000002595 magnetic resonance imaging Methods 0.000 claims description 55
- 239000000975 dye Substances 0.000 claims description 50
- 230000003287 optical effect Effects 0.000 claims description 41
- 238000003384 imaging method Methods 0.000 claims description 36
- 102000004190 Enzymes Human genes 0.000 claims description 17
- 108090000790 Enzymes Proteins 0.000 claims description 17
- 238000002591 computed tomography Methods 0.000 claims description 10
- 230000005298 paramagnetic effect Effects 0.000 claims description 9
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 8
- 150000002500 ions Chemical class 0.000 claims description 8
- 238000002600 positron emission tomography Methods 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 229910052688 Gadolinium Inorganic materials 0.000 claims description 6
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 claims description 6
- 239000011572 manganese Substances 0.000 claims description 6
- 230000004913 activation Effects 0.000 claims description 5
- 229910052692 Dysprosium Inorganic materials 0.000 claims description 4
- 229910052691 Erbium Inorganic materials 0.000 claims description 4
- 229910052693 Europium Inorganic materials 0.000 claims description 4
- 229910052689 Holmium Inorganic materials 0.000 claims description 4
- 229910052771 Terbium Inorganic materials 0.000 claims description 4
- 229910052775 Thulium Inorganic materials 0.000 claims description 4
- 229910052769 Ytterbium Inorganic materials 0.000 claims description 4
- 239000013522 chelant Substances 0.000 claims description 4
- KBQHZAAAGSGFKK-UHFFFAOYSA-N dysprosium atom Chemical compound [Dy] KBQHZAAAGSGFKK-UHFFFAOYSA-N 0.000 claims description 4
- UYAHIZSMUZPPFV-UHFFFAOYSA-N erbium Chemical compound [Er] UYAHIZSMUZPPFV-UHFFFAOYSA-N 0.000 claims description 4
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 claims description 4
- KJZYNXUDTRRSPN-UHFFFAOYSA-N holmium atom Chemical compound [Ho] KJZYNXUDTRRSPN-UHFFFAOYSA-N 0.000 claims description 4
- 229910052742 iron Inorganic materials 0.000 claims description 4
- 239000002105 nanoparticle Substances 0.000 claims description 4
- GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 claims description 4
- FRNOGLGSGLTDKL-UHFFFAOYSA-N thulium atom Chemical compound [Tm] FRNOGLGSGLTDKL-UHFFFAOYSA-N 0.000 claims description 4
- NAWDYIZEMPQZHO-UHFFFAOYSA-N ytterbium Chemical compound [Yb] NAWDYIZEMPQZHO-UHFFFAOYSA-N 0.000 claims description 4
- 229910052765 Lutetium Inorganic materials 0.000 claims description 3
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052779 Neodymium Inorganic materials 0.000 claims description 3
- 229910052777 Praseodymium Inorganic materials 0.000 claims description 3
- 229910052772 Samarium Inorganic materials 0.000 claims description 3
- OHSVLFRHMCKCQY-UHFFFAOYSA-N lutetium atom Chemical compound [Lu] OHSVLFRHMCKCQY-UHFFFAOYSA-N 0.000 claims description 3
- 229910052748 manganese Inorganic materials 0.000 claims description 3
- QEFYFXOXNSNQGX-UHFFFAOYSA-N neodymium atom Chemical compound [Nd] QEFYFXOXNSNQGX-UHFFFAOYSA-N 0.000 claims description 3
- 239000002907 paramagnetic material Substances 0.000 claims description 3
- PUDIUYLPXJFUGB-UHFFFAOYSA-N praseodymium atom Chemical compound [Pr] PUDIUYLPXJFUGB-UHFFFAOYSA-N 0.000 claims description 3
- KZUNJOHGWZRPMI-UHFFFAOYSA-N samarium atom Chemical compound [Sm] KZUNJOHGWZRPMI-UHFFFAOYSA-N 0.000 claims description 3
- 238000000799 fluorescence microscopy Methods 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 239000000463 material Substances 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000005291 magnetic effect Effects 0.000 abstract description 16
- 230000002255 enzymatic effect Effects 0.000 abstract description 5
- 239000000994 contrast dye Substances 0.000 abstract description 3
- 230000004807 localization Effects 0.000 abstract description 3
- 230000004071 biological effect Effects 0.000 abstract description 2
- 230000006870 function Effects 0.000 description 67
- 201000010099 disease Diseases 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 17
- 230000015572 biosynthetic process Effects 0.000 description 14
- 239000002405 nuclear magnetic resonance imaging agent Substances 0.000 description 14
- 238000003786 synthesis reaction Methods 0.000 description 14
- 238000010586 diagram Methods 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 7
- 229910021645 metal ion Inorganic materials 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- 230000005284 excitation Effects 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 102100024748 E3 ubiquitin-protein ligase UHRF2 Human genes 0.000 description 5
- 101710131422 E3 ubiquitin-protein ligase UHRF2 Proteins 0.000 description 5
- -1 Gd-DOPTA Chemical compound 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 229920001577 copolymer Polymers 0.000 description 5
- 239000012216 imaging agent Substances 0.000 description 5
- 230000004066 metabolic change Effects 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 230000031018 biological processes and functions Effects 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 125000002843 carboxylic acid group Chemical group 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000012631 diagnostic technique Methods 0.000 description 3
- GFSTXYOTEVLASN-UHFFFAOYSA-K gadoteric acid Chemical compound [Gd+3].OC(=O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 GFSTXYOTEVLASN-UHFFFAOYSA-K 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 210000005166 vasculature Anatomy 0.000 description 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000008045 co-localization Effects 0.000 description 2
- 238000002059 diagnostic imaging Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 210000001723 extracellular space Anatomy 0.000 description 2
- HZHFFEYYPYZMNU-UHFFFAOYSA-K gadodiamide Chemical compound [Gd+3].CNC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC(=O)NC HZHFFEYYPYZMNU-UHFFFAOYSA-K 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 description 2
- 229960004657 indocyanine green Drugs 0.000 description 2
- 210000003093 intracellular space Anatomy 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DOMDXTIMIZCSNC-UHFFFAOYSA-N (2Z)-2-[(2E,4E)-5-[3-[6-(2,5-dioxopyrrolidin-1-yl)oxy-6-oxohexyl]-1,1-dimethyl-6,8-disulfobenzo[e]indol-3-ium-2-yl]penta-2,4-dienylidene]-3-ethyl-1,1-dimethyl-8-sulfobenzo[e]indole-6-sulfonate Chemical compound CC1(C)C(C2=CC(=CC(=C2C=C2)S([O-])(=O)=O)S(O)(=O)=O)=C2N(CC)\C1=C/C=C/C=C/C(C(C1=C2C=C(C=C(C2=CC=C11)S(O)(=O)=O)S(O)(=O)=O)(C)C)=[N+]1CCCCCC(=O)ON1C(=O)CCC1=O DOMDXTIMIZCSNC-UHFFFAOYSA-N 0.000 description 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- 150000000921 Gadolinium Chemical class 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 238000012307 MRI technique Methods 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 102100030351 Membrane-associated phosphatidylinositol transfer protein 3 Human genes 0.000 description 1
- 101710104263 Membrane-associated phosphatidylinositol transfer protein 3 Proteins 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- FSUOQVGBXADQGH-UHFFFAOYSA-M [9-cyano-6-(diethylamino)xanthen-3-ylidene]-[6-(2,5-dioxopyrrolidin-1-yl)oxy-6-oxohexyl]-ethylazanium;chloride Chemical compound [Cl-].C1=C2OC3=CC(N(CC)CC)=CC=C3C(C#N)=C2C=CC1=[N+](CC)CCCCCC(=O)ON1C(=O)CCC1=O FSUOQVGBXADQGH-UHFFFAOYSA-M 0.000 description 1
- MXZROTBGJUUXID-UHFFFAOYSA-I [Gd+3].[O-]C(=O)CN(CC([O-])=O)CCN(CC(=O)[O-])CCN(CC([O-])=O)C(C([O-])=O)COCC1=CC=CC=C1 Chemical compound [Gd+3].[O-]C(=O)CN(CC([O-])=O)CCN(CC(=O)[O-])CCN(CC([O-])=O)C(C([O-])=O)COCC1=CC=CC=C1 MXZROTBGJUUXID-UHFFFAOYSA-I 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 239000003150 biochemical marker Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- PFYXSUNOLOJMDX-UHFFFAOYSA-N bis(2,5-dioxopyrrolidin-1-yl) carbonate Chemical compound O=C1CCC(=O)N1OC(=O)ON1C(=O)CCC1=O PFYXSUNOLOJMDX-UHFFFAOYSA-N 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960005063 gadodiamide Drugs 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940031182 nanoparticles iron oxide Drugs 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000863 peptide conjugate Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000001443 photoexcitation Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920005990 polystyrene resin Polymers 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000012857 radioactive material Substances 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- DBGVGMSCBYYSLD-UHFFFAOYSA-N tributylstannane Chemical compound CCCC[SnH](CCCC)CCCC DBGVGMSCBYYSLD-UHFFFAOYSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Radiology & Medical Imaging (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims (37)
- 磁気共鳴イメージング成分と活性化可能な光学イメージング成分を含む二元機能検出試薬であって、
磁気共鳴イメージング成分及び光学イメージング成分が単一の二元機能検出試薬に含まれており、活性化可能な光学イメージング成分が所定の事象の存在下でのみ活性化される、二元機能検出試薬。 - 前記磁気共鳴イメージング成分が常磁性材料及び超常磁性材料の1種類以上を含む、請求項1記載の二元機能検出試薬。
- 前記常磁性材料がキレート化ガドリニウム複合体、常磁性イオンのキレート及び被覆鉄ナノ粒子のうちの1種類以上を含む、請求項2記載の二元機能検出試薬。
- 前記常磁性イオンがマンガン(Mn)、プラセオジム(Pr)、ネオジム(Nd)、サマリウム(Sm)、ユウロピウム(Eu)、テルビウム(Tb)、ジスプロシウム(Dy)、ホルミウム(Ho)、エルビウム(Er)、ツリウム(Tm)、イッテルビウム(Yb)及びルテチウム(Lu)のうちの1種類以上を含む、請求項3記載の二元機能検出試薬。
- 前記超常磁性材料が超常磁性イオンのキレートを含む、請求項2記載の二元機能検出試薬。
- 前記超常磁性イオンがマンガン(Mn)、プラセオジム(Pr)、ネオジム(Nd)、サマリウム(Sm)、ユウロピウム(Eu)、テルビウム(Tb)、ジスプロシウム(Dy)、ホルミウム(Ho)、エルビウム(Er)、ツリウム(Tm)、イッテルビウム(Yb)及びルテチウム(Lu)のうちの1種類以上を含む、請求項5記載の二元機能検出試薬。
- 前記活性化可能な光学イメージング成分が1種類以上の光学染料を含む、請求項1記載の二元機能検出試薬。
- 前記活性化可能な光学イメージング成分がさらに1種類以上の消光剤を含む、請求項7記載の二元機能検出試薬。
- 前記磁気共鳴イメージング成分が活性化可能な光学イメージング成分に共有結合している、請求項1記載の二元機能検出試薬。
- 前記所定の事象が、所定の波長の光の存在、並びに所定の酵素の存在、蛍光活性化部位での酵素による切断、温度が所定の数値を上回った場合、温度が所定の数値を下回った場合、pHが所定の数値を上回った場合及びpHが所定の数値を下回った場合の少なくともいずれかを含む、請求項1記載の二元機能検出試薬。
- 前記磁気共鳴イメージング成分が常に活性化されている、請求項1記載の二元機能検出試薬。
- 前記磁気共鳴イメージング成分が生体から向上した解剖学的情報を与えることができる、請求項1記載の二元機能検出試薬。
- 前記活性化可能な光学イメージング成分が生体から向上した機能的情報を与えることができる、請求項1記載の二元機能検出試薬。
- 前記機能的情報が代謝情報を含む、請求項13記載の二元機能検出試薬。
- 生体の解剖学的情報を向上させることができる第一成分と生体の機能的情報を向上させることができる活性化可能な第二成分を含む二元機能検出試薬であって、
第一成分及び第二成分が単一の二元機能検出試薬に含まれており、活性化可能な第二成分が所定の事象の存在下でのみ活性化される、二元機能検出試薬。 - 第一イメージング成分が常に活性化されている、請求項15記載の二元機能検出試薬。
- 前記機能的情報が代謝情報を含む、請求項15記載の二元機能検出試薬。
- コンピュータ断層撮影、ポジトロン放出断層撮影及び磁気共鳴イメージングのうちの少なくともいずれかによって向上した解剖学的情報が得られる、請求項15記載の二元機能検出試薬。
- 前記向上した機能的情報が近赤外線蛍光イメージングで得られる、請求項15記載の二元機能検出試薬。
- 前記所定の事象が、所定の波長の光の存在、並びに所定の酵素の存在、蛍光活性化部位での酵素による切断、温度が所定の数値を上回った場合、温度が所定の数値を下回った場合、pHが所定の数値を上回った場合及びpHが所定の数値を下回った場合の少なくともいずれかを含む、請求項15記載の二元機能検出試薬。
- 生体における生化学的活性の高解像度インビボイメージングを得る方法であって、当該方法が、
生体の解剖学的情報の画像を取得する工程、及び
生体の機能的情報の画像を取得する工程
を含んでいて、生体内に二元機能検出試薬が存在しており、二元機能検出試薬が、生体の解剖学的情報を向上させることができる第一成分と生体の機能的情報を向上させることができる活性化可能な第二成分とを含んでおり、活性化可能な第二成分が所定の事象の存在下でのみ活性化される、方法。 - 前記機能的情報が代謝情報を含む、請求項21記載の方法。
- 取得工程を実施する前に、二元機能検出試薬を生体に投与する、請求項21記載の方法。
- 前記二元機能検出試薬が、静脈内、経口及び筋肉内のうちの少なくともいずれかの方法で投与される、請求項23記載の方法。
- 前記生体の解剖学的情報の画像が、コンピュータ断層撮影、ポジトロン放出断層撮影及び磁気共鳴イメージングのうちの少なくともいずれかで取得される、請求項21記載の方法。
- 前記生体の機能的情報の画像が光学イメージングで得られる、請求項21記載の方法。
- 前記取得工程が同時に実施される、請求項21記載の方法。
- 生体における生化学的活性の高解像度インビボ画像を得るためのシステムであって、当該システムが、
生体の解剖学的情報の画像を得るための二元機能検出試薬の第一イメージング成分を検出することができる第一イメージングデバイス、及び
生体の機能的情報の画像を得るための二元機能検出試薬の活性化可能な第二イメージング成分を検出することができる第二イメージングデバイスを備えており、
第一イメージングデバイス及び第二イメージングデバイスが同時に利用することができ、二元機能検出試薬の活性化可能な第二イメージング成分が所定の事象の存在下でのみ活性化される、システム。 - 前記機能的情報が代謝情報を含む、請求項31記載のシステム。
- 第一イメージングデバイスが、磁気共鳴イメージングデバイス、コンピュータ断層撮影デバイス及びポジトロン放出断層撮影デバイスのうちの少なくともいずれかを含む、請求項31記載のシステム。
- 第二イメージングデバイスが光学イメージングデバイスを含む、請求項31記載のシステム。
- 第一イメージングデバイス及び第二イメージングデバイスが同時に利用される、請求項31記載のシステム。
- 第一イメージングデバイスが磁気共鳴イメージングデバイスを含み、第二イメージングデバイスが光学イメージングデバイスを含む、請求項31記載のシステム。
- 第一イメージングデバイス及び第二イメージングデバイスが同時に利用される、請求項36記載のシステム。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/252,311 US7303741B2 (en) | 2002-09-23 | 2002-09-23 | Systems and methods for high-resolution in vivo imaging of biochemical activity in a living organism |
PCT/US2003/025184 WO2004026344A1 (en) | 2002-09-23 | 2003-08-11 | Bifunctional contrast agent comprising a fluorescent dye and an mri contrast agent |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006511473A true JP2006511473A (ja) | 2006-04-06 |
JP2006511473A5 JP2006511473A5 (ja) | 2006-09-28 |
Family
ID=31992929
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004537651A Pending JP2006511473A (ja) | 2002-09-23 | 2003-08-11 | 蛍光染料及びmri造影剤を含む二元機能造影剤 |
Country Status (6)
Country | Link |
---|---|
US (2) | US7303741B2 (ja) |
EP (1) | EP1545629A1 (ja) |
JP (1) | JP2006511473A (ja) |
CN (1) | CN1684710A (ja) |
AU (1) | AU2003259769A1 (ja) |
WO (1) | WO2004026344A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009535126A (ja) * | 2006-04-27 | 2009-10-01 | バーンズ−ジューイッシュ ホスピタル | 標的組織の検出とイメージング |
WO2011109216A3 (en) * | 2010-03-01 | 2012-01-12 | University Of Florida Research Foundation, Inc. | Nir materials and nanomaterials for theranostic applications |
JP2012183308A (ja) * | 2011-03-03 | 2012-09-27 | Imris Inc | Mr磁石のボアで使用するためのmr適合性の蛍光表示デバイス |
WO2012128162A1 (ja) | 2011-03-18 | 2012-09-27 | コニカミノルタエムジー株式会社 | 画像診断用シリカナノ粒子、その製造方法、及び生体物質標識剤 |
JP2012525883A (ja) * | 2009-05-05 | 2012-10-25 | ルミト・アーベー | 散乱媒体の拡散ルミネセンスイメージングまたは断層撮影の改善のためのシステム、方法、およびルミネセンスマーカー |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE536993T1 (de) | 2002-01-02 | 2011-12-15 | Visen Medical Inc | Aminfunktionalisierte superparamagnetisierte nanoteilchen für die synthese von biokonjugaten |
WO2005017539A2 (en) * | 2003-08-14 | 2005-02-24 | The General Hospital Corporation | Imaging pathology |
US20050152842A1 (en) * | 2003-12-24 | 2005-07-14 | Chun Li | Poly (L-glutamic acid) paramagnetic material complex and use as a biodegradable MRI contrast agent |
KR101313712B1 (ko) * | 2005-01-05 | 2013-10-01 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 이중 영상화 및 방사선화학요법용 접합체: 조성물,제조방법 및 적용 |
DE602005010747D1 (de) | 2005-01-13 | 2008-12-11 | Cinv Ag | Kohlenstoffnanopartikel enthaltende verbundwerkstoffe |
FI20055653A (fi) * | 2005-12-08 | 2007-06-09 | Wallac Oy | Leimausreagenssi |
US9913917B2 (en) | 2005-12-22 | 2018-03-13 | Visen Medical, Inc. | Biocompatible fluorescent metal oxide nanoparticles |
US20070148094A1 (en) * | 2005-12-22 | 2007-06-28 | Uzgiris Egidijus E | Polymeric imaging agents and medical imaging methods |
DE102006021317B3 (de) * | 2006-05-06 | 2007-10-11 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Verfahren und Fluoreszenzlichtmikroskop zum räumlich hochauflösenden Abbilden einer Struktur einer Probe |
US20080154102A1 (en) * | 2006-07-03 | 2008-06-26 | Frangioni John V | Intraoperative imaging methods |
US7906106B2 (en) * | 2007-06-27 | 2011-03-15 | General Electric Company | In vivo cell trafficking |
US8021647B2 (en) | 2007-06-29 | 2011-09-20 | General Electric Company | In vivo optical imaging |
KR20100127845A (ko) | 2008-03-24 | 2010-12-06 | 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 | 심근 질환의 영상-유도된 치료: 조성물, 제조 및 적용 |
WO2009121055A1 (en) * | 2008-03-28 | 2009-10-01 | Georgia Tech Research Corporation | Reduced dye probes for the detection of radical oxygen species |
US8758727B2 (en) * | 2008-03-31 | 2014-06-24 | University Of Louisville Research Foundation, Inc. | Site specific fluorescence and contrast marker for same |
US8440167B2 (en) * | 2008-10-27 | 2013-05-14 | University Of Virginia Patent Foundation | Multimodal imaging of atherosclerotic plaque targeted to LOX-1 |
CN101554481B (zh) * | 2009-05-19 | 2011-04-13 | 泸州医学院附属医院 | 用于spect和mri的双功能显像剂及其制备方法 |
US8834846B2 (en) | 2010-05-06 | 2014-09-16 | Bruker Biospin Corporation | Fluorescent NIRF activatable probes for disease detection |
WO2012047841A2 (en) * | 2010-10-04 | 2012-04-12 | Nuovoprobe Ltd. | System and method for electromagnetic imaging and therapeutics using specialized nanoparticles |
KR101352342B1 (ko) * | 2010-11-24 | 2014-02-17 | 서울대학교산학협력단 | 코어 물질과 쉘 물질 사이에 나노갭이 형성된 단일 나노입자 및 이의 제조방법 |
CN102167813B (zh) * | 2011-01-19 | 2012-08-08 | 兰州大学 | 一种荧光示踪纳米磁共振成像造影剂 |
CN102166365B (zh) * | 2011-04-25 | 2012-10-24 | 东南大学 | 一种多模态碘油纳米乳造影剂的制备方法 |
CN102397562B (zh) * | 2011-11-23 | 2012-11-28 | 南昌大学 | 一种由普鲁士蓝负载Gd3+的造影剂的制备方法 |
US9492571B2 (en) * | 2012-06-01 | 2016-11-15 | University Of Massachusetts | Molecular probes for multimodality imaging and tracking of stem cells |
US9903821B2 (en) | 2013-05-01 | 2018-02-27 | Indian Institute Of Technology Madras | Coated mesoflowers for molecular detection and smart barcode materials |
KR101567157B1 (ko) * | 2013-12-13 | 2015-11-09 | 경북대학교 산학협력단 | Mri/fi 조영제 및 이의 제조방법 |
US10570173B2 (en) | 2015-01-22 | 2020-02-25 | The Board Of Trustees Of The Leland Stanford Junior University | Protease-activated contrast agents for in vivo imaging |
CN110678460A (zh) | 2017-03-30 | 2020-01-10 | 里兰斯坦福初级大学理事会 | 用于体内成像的蛋白酶激活的造影剂 |
CN107384385B (zh) * | 2017-07-31 | 2020-10-30 | 中山大学 | MR/FL双模态成像探针及其制备方法以及掺杂Ho碳量子点的用途 |
US20220062444A1 (en) * | 2018-12-18 | 2022-03-03 | Bracco Imaging S.P.A. | Pharmaceutical compositions comprising gd-complexes and polyarylene additives |
CN110665015A (zh) * | 2019-10-23 | 2020-01-10 | 中山大学 | 一种肿瘤微环境响应型荧光/磁共振双模态成像探针 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5900228A (en) * | 1996-07-31 | 1999-05-04 | California Institute Of Technology | Bifunctional detection agents having a polymer covalently linked to an MRI agent and an optical dye |
JP2001503748A (ja) * | 1996-10-30 | 2001-03-21 | フォトゲン インク. | 分子薬の光活性における選択性改善と検出のための方法 |
WO2001082974A2 (en) * | 2000-04-21 | 2001-11-08 | Bracco Imaging S.P.A. | Use of bile acid derivatives conjugated with metal ion chelated complexes for the diagnostic assessment of microvascular permeability |
JP2002514610A (ja) * | 1998-05-14 | 2002-05-21 | ザ ジュネラル ホスピタル コーポレーション | 分子内発光抑制式近赤外蛍光プローブ |
JP2002220348A (ja) * | 1985-05-08 | 2002-08-09 | General Hospital Corp | 肝臓胆管のnmrコントラスト剤 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6592847B1 (en) | 1998-05-14 | 2003-07-15 | The General Hospital Corporation | Intramolecularly-quenched near infrared flourescent probes |
US6217848B1 (en) * | 1999-05-20 | 2001-04-17 | Mallinckrodt Inc. | Cyanine and indocyanine dye bioconjugates for biomedical applications |
-
2002
- 2002-09-23 US US10/252,311 patent/US7303741B2/en not_active Expired - Fee Related
-
2003
- 2003-08-11 AU AU2003259769A patent/AU2003259769A1/en not_active Abandoned
- 2003-08-11 WO PCT/US2003/025184 patent/WO2004026344A1/en active Application Filing
- 2003-08-11 EP EP03797836A patent/EP1545629A1/en not_active Ceased
- 2003-08-11 JP JP2004537651A patent/JP2006511473A/ja active Pending
- 2003-08-11 CN CN03822648.0A patent/CN1684710A/zh active Pending
-
2007
- 2007-10-19 US US11/875,245 patent/US20080118439A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002220348A (ja) * | 1985-05-08 | 2002-08-09 | General Hospital Corp | 肝臓胆管のnmrコントラスト剤 |
US5900228A (en) * | 1996-07-31 | 1999-05-04 | California Institute Of Technology | Bifunctional detection agents having a polymer covalently linked to an MRI agent and an optical dye |
US6123921A (en) * | 1996-07-31 | 2000-09-26 | California Institute Of Technology | Bifunctional detection agents having an optical dye linked to an MRI contrast agent |
JP2001503748A (ja) * | 1996-10-30 | 2001-03-21 | フォトゲン インク. | 分子薬の光活性における選択性改善と検出のための方法 |
JP2002514610A (ja) * | 1998-05-14 | 2002-05-21 | ザ ジュネラル ホスピタル コーポレーション | 分子内発光抑制式近赤外蛍光プローブ |
WO2001082974A2 (en) * | 2000-04-21 | 2001-11-08 | Bracco Imaging S.P.A. | Use of bile acid derivatives conjugated with metal ion chelated complexes for the diagnostic assessment of microvascular permeability |
Non-Patent Citations (2)
Title |
---|
JPN7009004255, JOSEPHSON,L. et al, "Near−infrared fluorescent nanoparticles as combined MR/optical imaging probes", Bioconjug Chem, 2002, Vol.13, No.3, p.554−60 * |
JPN7009004256, HUBER,M.M. et al, "Fluorescently detectable magnetic resonance imaging agents", Bioconjug Chem, 1998, Vol.9, No.2, p.242−9 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009535126A (ja) * | 2006-04-27 | 2009-10-01 | バーンズ−ジューイッシュ ホスピタル | 標的組織の検出とイメージング |
JP2012525883A (ja) * | 2009-05-05 | 2012-10-25 | ルミト・アーベー | 散乱媒体の拡散ルミネセンスイメージングまたは断層撮影の改善のためのシステム、方法、およびルミネセンスマーカー |
US9012869B2 (en) | 2009-05-05 | 2015-04-21 | Lumito Ab | System, method, and luminescent marker for improved diffuse luminescent imaging or tomography in scattering media |
JP2016135316A (ja) * | 2009-05-05 | 2016-07-28 | ルミト・アーベー | 散乱媒体の拡散ルミネセンスイメージングまたは断層撮影の改善のためのシステム、方法、およびルミネセンスマーカー |
JP2018128470A (ja) * | 2009-05-05 | 2018-08-16 | ルミト・アーベー | 散乱媒体の拡散ルミネセンスイメージングまたは断層撮影の改善のためのシステム、方法、およびルミネセンスマーカー |
WO2011109216A3 (en) * | 2010-03-01 | 2012-01-12 | University Of Florida Research Foundation, Inc. | Nir materials and nanomaterials for theranostic applications |
JP2012183308A (ja) * | 2011-03-03 | 2012-09-27 | Imris Inc | Mr磁石のボアで使用するためのmr適合性の蛍光表示デバイス |
WO2012128162A1 (ja) | 2011-03-18 | 2012-09-27 | コニカミノルタエムジー株式会社 | 画像診断用シリカナノ粒子、その製造方法、及び生体物質標識剤 |
JPWO2012128162A1 (ja) * | 2011-03-18 | 2014-07-24 | コニカミノルタ株式会社 | 画像診断用シリカナノ粒子、その製造方法、及び生体物質標識剤 |
Also Published As
Publication number | Publication date |
---|---|
US20040057903A1 (en) | 2004-03-25 |
US7303741B2 (en) | 2007-12-04 |
EP1545629A1 (en) | 2005-06-29 |
WO2004026344A1 (en) | 2004-04-01 |
US20080118439A1 (en) | 2008-05-22 |
AU2003259769A1 (en) | 2004-04-08 |
CN1684710A (zh) | 2005-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7303741B2 (en) | Systems and methods for high-resolution in vivo imaging of biochemical activity in a living organism | |
Nagaya et al. | Fluorescence-guided surgery | |
Bu et al. | Fluorescent imaging of cancerous tissues for targeted surgery | |
Frullano et al. | Multimodal MRI contrast agents | |
Oostendorp et al. | Quantitative molecular magnetic resonance imaging of tumor angiogenesis using cNGR-labeled paramagnetic quantum dots | |
US7338651B2 (en) | Multi-use multimodal imaging chelates | |
RU2450832C2 (ru) | Контрастные вещества для детекции рака предстательной железы | |
Berezin et al. | Rational approach to select small peptide molecular probes labeled with fluorescent cyanine dyes for in vivo optical imaging | |
Jain et al. | Diagnostic nanocarriers for sentinel lymph node imaging | |
Bai et al. | Recent advances in receptor-targeted fluorescent probes for in vivo cancer imaging | |
Alford et al. | Molecular probes for the in vivo imaging of cancer | |
US20060204443A1 (en) | Methods for tumor treatment using dendrimer conjugates | |
JP6174713B2 (ja) | 新規な癌病変標識用組成物 | |
CN107652358A (zh) | 一种uPAR靶向性多肽、探针和活体分子显像方法 | |
US9200017B2 (en) | Multimodal imaging of fibrin | |
Qiao et al. | Molecular imaging of EGFR/HER2 cancer biomarkers by protein MRI contrast agents | |
CN104483296B (zh) | 乳腺癌分子探针及其制造方法 | |
McCann et al. | Molecular imaging of tumor invasion and metastases: the role of MRI | |
Johansen et al. | Quantitative molecular imaging with a single Gd-based contrast agent reveals specific tumor binding and retention in vivo | |
Harney et al. | Molecular imaging of in vivo gene expression | |
Liu et al. | Nanotechnology for cancer imaging: advances, challenges, and clinical opportunities | |
Lucarelli et al. | New approaches to lymphatic imaging | |
Song et al. | Tumor-targetable magnetoluminescent silica nanoparticles for bimodal time-gated luminescence/magnetic resonance imaging of cancer cells in vitro and in vivo | |
Cheng et al. | Non-invasive molecular imaging for precision diagnosis of metastatic lymph nodes: opportunities from preclinical to clinical applications | |
Lv et al. | Advances and Perspectives of Peptide and Polypeptide‐Based Materials for Biomedical Imaging |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060808 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060808 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090915 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091215 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20091215 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20091215 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091222 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100315 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100608 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100908 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100915 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101108 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110215 |